Haemonetics Corporation
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Haemonetics Corporation (NYSE: HAE) develops, manufactures and markets innovative medical technologies and software solutions that address blood management needs; the company offers automated blood collection and processing systems including the NexSys PCS plasmapheresis platform with Persona technology and Express Plus software, cell salvage autotransfusion devices such as the Cell Saver Elite+ with Intelligent Control, hemostasis analyzers like the TEG 6s with Global Hemostasis-HN cartridge, vascular closure systems including the VASCADE portfolio, interventional guidewires from SavvyWire and OptoWire via OpSens, esophageal cooling devices such as ensoETM from Attune Medical, and blood management software encompassing BloodTrack HaemoBank, SafeTrace Tx transfusion management and NexLynk DMS; Haemonetics serves hospitals, plasma collection centers, blood banks and surgical suites with products that enhance patient outcomes, improve operational efficiency and ensure blood safety. Founded in 1971 and headquartered in Boston, Massachusetts, the company maintains global operations across North America, Europe, Asia-Pacific and Latin America, with manufacturing facilities including sites in the United States and Mexico. In recent developments, Haemonetics announced in December 2024 a binding agreement to divest its Transfusion Medicine whole blood business—including blood collection, processing, filtration and transfusion solutions—to GVS S.p.A. for up to $67.1 million with closure expected in Q1 2025; the company completed acquisitions of Attune Medical in 2024 adding the ensoETM device, launched the TEG 6s Global Hemostasis-HN cartridge and earned CE Mark for SavvyWire in 2024, acquired OpSens Inc. in 2023 for guidewire technologies, and secured FDA clearances and international approvals for plasma and vascular products in 2023.
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Haemonetics Corp (HAE) Stock Up 6.5% and Still Undervalued -- GF Score: 84/100
BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
Pharvaris Announces Annual General Meeting of Shareholders
Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Haemonetics Updates Financial Reporting Segments
Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends
Is It Too Late to Buy Haemonetics Corp (HAE) After 4.0% Rally? GF Value Says Undervalued
Is the Options Market Predicting a Spike in Haemonetics Stock?
Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
HAE Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Cut
Haemonetics Q4 Earnings Call Highlights
The London Company Small Cap Portfolio Q1 2026 Portfolio Review
Haemonetics Corporation (HAE) Q4 2026 Earnings Call Transcript
Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say